Clean Power Hydrogen signs convertible loan note term sheet By Investing.com

Clean Power Hydrogen agreed a binding term sheet for a £750,000 convertible loan note with Hidrigin, carrying 10% interest and a 46% conversion discount, conditional on CPH2 raising at least £3 million. The financing is secured by a first-ranking floating charge and includes a nine-month exclusivity period to negotiate a strategic partnership, potentially making Hidrigin CPH2’s exclusive manufacturing partner across key markets. The deal is supportive for liquidity and partnership optionality, but it remains subject to definitive documentation and approvals.

Analysis

This is less a capital raise signal than a control transfer embedded in financing terms. A first-lien-like claim on assets plus a deep reset-style conversion structure typically shifts bargaining power toward the new capital provider and away from minority holders; that can stabilize near-term solvency, but it usually comes at the cost of future equity overhang and depressed follow-on financing terms for any existing shareholders.

The bigger second-order effect is on counterparties. By effectively ring-fencing a strategic manufacturing relationship, Hidrigin may be trying to de-risk supply execution, but exclusivity can also narrow CPH2’s addressable buyer base and reduce pricing leverage with alternative partners. Competitors in electrolyzer and adjacent green-hydrogen equipment markets benefit if this process drags on, because customers tend to avoid vendors whose funding runway is uncertain and whose commercial structure is being renegotiated.

Over the next 1-3 months, the key catalyst is not the note itself but whether the company can clear the minimum equity raise condition. Failure to do so would likely force a second restructuring step, with a materially worse outcome for common equity and a higher probability that the asset package becomes the only remaining value anchor. If the raise succeeds, the immediate relief rally could still fade as the market prices in a discounted conversion, governance complexity, and the possibility that the strategic partnership becomes economically binding before the business is proven.

Consensus is probably overrating the word “partnership” and underpricing the dilution path. The relevant question is whether this is a bridge to scale or a staged recapitalization that buys time while preserving optionality for the new money; given the terms, the latter looks more plausible. In that scenario, the tradeable edge is not a directional long on the company, but a view that any bounce should be sold into rather than chased.

Key Decisions for Investors

• Avoid initiating a long in CPH2 common until the £3m equity condition is visibly underwritten; if the raise closes, expect another 20-40% dilution-equivalent pressure from the reset-style conversion terms over the next 1-2 quarters.
• If borrow is available, consider a small tactical short in CPH2 into any financing-led bounce, targeting a 4-8 week horizon; risk is capped by deal completion and a takeout, but upside should be limited by the discount-to-equity structure.
• Pair: short weaker pre-profit clean-tech balance sheets versus long better-capitalized hydrogen exposure or broader renewables basket, as financing differentiation should widen over the next 6-12 months.
• For event-driven desks, wait for definitive docs before trading the strategic partnership angle; the cleanest catalyst is a failed fundraise or missed deadline, which would likely create the highest convex downside in the equity.